UK Subscription model goes live! Value bands cover entire UK!
Dear All (with thanks to Kevin for leading on this newsletter and with a wonkish / long-read alert on this email … settle in for
19 August 2024
No Comments
R&D Insight
The global funding pipeline, 2017-2023: A review
Dear All, In a thoughtful companion to WHO’s preclinical and clinical pipeline reviews, we now have an instructive analysis of the global funding pipeline for
7 February 2026
No Comments
Interactive dashboard for WHO’s antibacterial pipeline reviews
Dear All, I wrote in the 4 Oct 2025 newsletter about WHO’s updated reviews of antibacterial therapeutics and diagnostics. Team WHO have now released dashboard versions of
9 November 2025
No Comments
FDA analysis of 40-years of antibacterial development: Dheman et al.
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Just out in CID is a paper in which FDA analyzes trends in
30 June 2020
No Comments
WHO Bacterial Priority Pathogen List (PPL): 2024 update
Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO
18 May 2024
No Comments
Antibacterial R&D is very hard! Two great pipeline reviews + an Industry-level view
Dear All (and with thanks to Stephan Harbarth for co-authoring this newsletter), A new review by Ursula Theuretzbacher and colleagues from GARDP provides an opportunity
4 April 2025
No Comments
AMR in India: A possible global future unless we act now!
Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research (ICMR) released its report on
2 December 2025
No Comments
Leaving the lab: The decline in AMR R&D professionals
Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals”
8 February 2024
No Comments
FDA RFPs: Susceptibility breakpoints and external controls for invasive fungal infections
Dear All, I just today learned that FDA has posted two antimicrobial resistance-related (AMR-related) FY 2026 funding opportunities. The titles for the RFPs are very
5 February 2026
No Comments
Manufacturing underpins both access and stewardship: Cefiderocol as a case study
Update: There is a 14 April 2025 follow-up to this newsletter. Dear All, Prompted by an excellent talk by GARDP’s Jennifer Cohn at last week’s
25 September 2023
No Comments